A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes

Inclusion Criteria: * Have T2DM controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (metformin or dipeptidyl peptidase \[DPP\]-IV inhibitors) * Have a body mass index of 20.0 to 35.0 kilograms per square meter, inclusive Exclusion Criteria: * Have known allergies to tirzepatide, glucagon-like peptide (GLP)-1 analogs, or related compounds * Have had more than 1 episode of severe hypoglycemia, as defined by the American Diabetes Association criteria, within 6 months before entry into the study or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms * Have an abnormality in the 12-lead electrocardiogram at screening that, in the opinion of the investigator, increases the risks associated with participating in the study * Have a history or presence of pancreatitis or gastrointestinal (GI) disorder or any GI disease which impacts gastric emptying or could be aggravated by GLP-1 analogs or DPP-IV inhibitors